Skip to search formSkip to main contentSkip to account menu

atezolizumab

Known as: anti-PDL1, immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer 
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune… 
National Institutes of Health

Related topics

Related topics

7 relations
20 ML atezolizumab 60 MG/ML Injection [Tecentriq]Antibodies, Monoclonal, HumanizedMonoclonal AntibodiesNCIt Antineoplastic Agent Terminology

Broader (1)

Antineoplastic Agents

Narrower (1)

MPDL3280A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
5000Background: Radical surgery ± cisplatin-based neoadjuvant chemo (NAC) is the mainstay treatment (tx) for MIUC, with no… 
2020
2020
Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors
Highly Cited
2019
Highly Cited
2019
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally…
1003 Background: IMpassion130 evaluated atezo (anti–PD-L1) + nP vs placebo + nP in 1L mTNBC. The primary PFS analysis found that… 
2018
2018
Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).
8532Background: Neoadjuvant chemotherapy is an accepted treatment approach for resectable NSCLC. Major pathologic response (mPR… 
Highly Cited
2018
Highly Cited
2018
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
8541Background: Platinum-based chemotherapy, before or after surgery, provides only a 5% benefit in 5yr. OS in locally advanced… 
Highly Cited
2017
Highly Cited
2017
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
2017
2017
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
3063Background: Targeted inhibition of MEK with C and BRAF with V in BRAFV600-mutant mel can lead to both anticancer immune… 
2016
2016
Despite slow progress, bispecifics generate buzz
Highly Cited
2015
Highly Cited
2015
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
8030 Background: MPDL3280A, which preserves the PD-L2/PD-1 interaction to potentially diminish autoimmune lung toxicity, has… 
2014
2014
Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.
2602 Background: MEDI4736 is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human programmed death… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)